US FDA declines to approve Corcept’s drug for rare hormonal disorder
By Sneha S K and Sahil Pandey Dec 31 (Reuters) – The U.S. Food and Drug Administration has…
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
REDWOOD CITY, Calif., December 31, 2025–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery…